Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia - Clinicopathologic features of 12 cases

被引:75
作者
Lin, P [1 ]
Mansoor, A [1 ]
Bueso-Ramos, C [1 ]
Hao, SY [1 ]
Lai, R [1 ]
Medeiros, LJ [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
关键词
large cell lymphoma; lymphoplasmacytic lymphoma; Waldenstrom macroglobulinemia;
D O I
10.1039/R01VXG46MFCDVNHL
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Of 92 patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM) treated at our institution, diffuse large B-cell lymphoma (DLBCL) also developed in 12 (13%). In 10 patients, DLBCL developed 12 to 128 months (median, 44 months) after the diagnosis of LPL/WM. Two patients had LPL/WM and DLBCL simultaneously. Clinicopathologic features at diagnosis of LPL/WM did not predict the risk of DLBCL. Onset of DLBCL was characterized by worsening constitutional symptoms, profound cytopenias, extramedullary disease, and organomegaly. Immunoglobulin light chain expression was identical in both LPL/WM and DLBCL. In situ hybridization for Epstein-Barr virus (EBV) in 8 cases of DLBCL was negative. Of 11 patients with clinical follow-up information available, 8 (73%) died within 10 months of diagnosis of DLBCL. DLBCL, most likely as a result of histologic transformation, occurs in a subset of patients with LPL/WM and is associated with aggressive clinical course and poor outcome. EBV is unlikely to be involved in transformation.
引用
收藏
页码:246 / 253
页数:8
相关论文
共 31 条
[1]  
Abe K, 1996, ACTA OTO-LARYNGOL, P259
[2]  
[Anonymous], 2001, World Health Organization Classification of Tumours Tumors of Haematopoietic and Lymphoid Tissues
[3]   Cutaneous Waldenstrom macroglobulinemia in transformation [J].
Appenzeller, P ;
Leith, CP ;
Foucar, K ;
Scott, AA ;
Bigler, CF ;
Thompson, CT .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1999, 21 (02) :151-155
[4]  
BARTL R, 1983, SCAND J HAEMATOL, V31, P359
[5]  
CHOI YJ, 1979, AM J CLIN PATHOL, V71, P121
[6]  
CHUBACHI A, 1991, CANCER, V68, P781, DOI 10.1002/1097-0142(19910815)68:4<781::AID-CNCR2820680420>3.0.CO
[7]  
2-6
[8]   Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003) [J].
Dhodapkar, MV ;
Jacobson, JL ;
Gertz, MA ;
Crowley, JJ ;
Barlogie, B .
SEMINARS IN ONCOLOGY, 2003, 30 (02) :220-225
[9]  
DIMOPOULOS MA, 1994, BLOOD, V83, P1452
[10]  
FOUCAR K, 1980, CANCER, V46, P118, DOI 10.1002/1097-0142(19800701)46:1<118::AID-CNCR2820460120>3.0.CO